Recently, several clinical leukemia events reported by Hacein-Bey-Abina et al. in severe combined immunodeficiency-X linked (SCID-X) patients treated with γ-chain transduced CD34+ cells [29] raised questions about the general safety of retrovirus-based gene therapy. This evidence concerns the gene CD34 and leukemia.